Drugs / Filgastrim
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03549728 | Jun → Oct 2018 | endometriosis, infertility disorder | Amira Magdi Guergues Selim | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00163761 Comparator | Dec 2002 → Feb 2008 | Hodgkins lymphoma, non-Hodgkin lymphoma | Bayside Health | Completed | No outcome recorded |
| Phase 3 | NCT02319135 Comparator | Oct 2014 → Oct 2018 | acute myeloid leukemia | PETHEMA Foundation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | filgastrim | “30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion” NCT03549728 ↗ |
| Known as | filgrastim | “Priming with daily administration of subcutaneous G-CSF (lenograstim or filgrastim 5 mcg /kg / day, days -1, 1 and 2)” NCT02319135 ↗ |
| Known as | G-CSF | “30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion” NCT03549728 ↗ |
| Route | Subcutaneous | “Priming with daily administration of subcutaneous G-CSF (lenograstim or filgrastim 5 mcg /kg / day, days -1, 1 and 2)” NCT02319135 ↗ |